Literature DB >> 31401687

The factors related to the poor ADL in the patients with osteoporotic vertebral fracture after instrumentation surgery.

Kazuma Murata1, Yuji Matsuoka2, Hirosuke Nishimura2, Kenji Endo2, Hidekazu Suzuki2, Taichiro Takamatsu2, Yasunobu Sawaji2, Takato Aihara2, Takuya Kusakabe2, Asato Maekawa2, Kengo Yamamoto2, Kei Watanabe3, Takashi Kaito4, Hidetomi Terai5, Koji Tamai5, Atushi Tagami6, Toshitaka Yoshii7, Katsumi Harimaya8, Kenichi Kawaguchi8, Atsushi Kimura9, Gen Inoue10, Atsushi Nakano11, Daisuke Sakai12, Akihiko Hiyama12, Shota Ikegami13, Seiji Ohtori14, Takeo Furuya14, Sumihisa Orita14, Shiro Imagama15, Kazuyoshi Kobayashi15, Katsuhito Kiyasu16, Hideki Murakami17, Katsuhito Yoshioka17, Shoji Seki18, Michio Hongo19, Kenichiro Kakutani20, Takashi Yurube20, Yasuchika Aoki21, Hiroshi Uei22, Yasumitsu Ajiro22, Masahiko Takahata23, Hirooki Endo24, Tetsuya Abe25, Kazuyoshi Nakanishi26, Kota Watanabe27, Eijiro Okada27, Naobumi Hosogane28, Haruki Funao29, Norihiro Isogai29, Ken Ishii29.   

Abstract

PURPOSE: Osteoporotic vertebral fracture (OVF) with nonunion or neurological deficit may be a candidate for surgical treatment. However, some patients do not show improvement as expected. Therefore, we conducted a nationwide multicenter study to determine the predictors for postoperative poor activity of daily living (ADL) in patients with OVF.
METHODS: We retrospectively reviewed the case histories of 309 patients with OVF who underwent surgery. To determine the factors predicting postoperative poor ADL, uni- and multivariate statistical analyses were performed.
RESULTS: The frequency of poor ADL at final follow-up period was 9.1%. In univariate analysis, preoperative neurological deficit (OR, 4.1; 95% CI, 1.8-10.3; P < 0.001), perioperative complication (OR, 3.4; P = 0.006), absence of preoperative bone-modifying agent (BMA) administration (OR, 2.7; P = 0.03), and absence of postoperative recombinant human parathyroid hormone (rPTH) administration (OR, 3.9; P = 0.006) were significantly associated. In multivariate analysis, preoperative neurological deficit (OR, 4.6; P < 0.001), perioperative complication (OR, 3.4; P = 0.01), and absence of postoperative rPTH administration (OR, 3.9; P = 0.02) showed statistical significance.
CONCLUSIONS: Preoperative neurological deficit, perioperative complication, and absence of postoperative rPTH administration were considered as predictors for postoperative poor ADL in patients with OVF. Neurological deficits and complications are often inevitable factors; therefore, rPTH is an important option for postoperative treatment for OVF. These slides can be retrieved under Electronic Supplementary Material.

Entities:  

Keywords:  Activity of daily living; Osteoporotic vertebral fracture; Parathyroid hormone

Mesh:

Year:  2019        PMID: 31401687     DOI: 10.1007/s00586-019-06092-0

Source DB:  PubMed          Journal:  Eur Spine J        ISSN: 0940-6719            Impact factor:   3.134


  3 in total

1.  Surgical treatment of complete fifth lumbar osteoporotic vertebral burst fracture: A retrospective case report of three patients.

Authors:  Kazunobu Abe; Naohisa Miyakoshi; Takashi Kobayashi; Michio Hongo; Yuji Kasukawa; Yoshinori Ishikawa; Daisuke Kudo; Eiji Abe; Yoichi Shimada
Journal:  Surg Neurol Int       Date:  2020-12-16

Review 2.  Locomotive syndrome in cancer patients: a new role of orthopaedic surgeons as a part of comprehensive cancer care.

Authors:  Hirotaka Kawano; Masahiro Hirahata; Jungo Imanishi
Journal:  Int J Clin Oncol       Date:  2022-06-11       Impact factor: 3.850

3.  Artificial intelligence for the detection of vertebral fractures on plain spinal radiography.

Authors:  Kazuma Murata; Kenji Endo; Takato Aihara; Hidekazu Suzuki; Yasunobu Sawaji; Yuji Matsuoka; Hirosuke Nishimura; Taichiro Takamatsu; Takamitsu Konishi; Asato Maekawa; Hideya Yamauchi; Kei Kanazawa; Hiroo Endo; Hanako Tsuji; Shigeru Inoue; Noritoshi Fukushima; Hiroyuki Kikuchi; Hiroki Sato; Kengo Yamamoto
Journal:  Sci Rep       Date:  2020-11-18       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.